How to buy Ocular Therapeutix stock (OCUL)

Ocular Therapeutix is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.44 – a decrease of 5.06% over the previous week. Ocular Therapeutix employs 267 staff and has a trailing 12-month revenue of around $61.1 million.

Our top picks for where to buy Ocular Therapeutix stock

Buy Ocular Therapeutix stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ocular Therapeutix stock price (NASDAQ: OCUL)

Use our graph to track the performance of OCUL stocks over time.

Ocular Therapeutix shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$8.44
52-week range	$3.76 - $11.78
50-day moving average more info button	$10.03
200-day moving average more info button	$8.20
Wall St. target price	$18.22
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.29

Is it a good time to buy Ocular Therapeutix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocular Therapeutix price performance over time

Historical closes compared with the close of $9.02 from 2024-12-17

1 week (2024-12-12)	1.46%
1 month (2024-11-20)	2.73%
3 months (2024-09-19)	-0.22%
6 months (2024-06-18)	64.30%

1 year (2023-12-19)	123.27%
2 years (2022-12-19)	244.27%
3 years (2021-12-17)	29.04%
5 years (2019-12-19)	130.10%

Ocular Therapeutix financials

Revenue TTM	$61.1 million
Gross profit TTM	$-6,508,000
Return on assets TTM	-22.37%
Return on equity TTM	-72.67%
Profit margin	-226.46%
Book value	$0.79
Market Capitalization more info button	$1.3 billion

TTM: trailing 12 months

Ocular Therapeutix share dividends

We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.

Ocular Therapeutix share price volatility

Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $3.7599 up to $11.775. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 1.256. This would suggest that Ocular Therapeutix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ocular Therapeutix overview

Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.

Frequently asked questions

What percentage of Ocular Therapeutix is owned by insiders or institutions?
Currently 1.06% of Ocular Therapeutix shares are held by insiders and 91.078% by institutions. How many people work for Ocular Therapeutix?
Latest data suggests 267 work at Ocular Therapeutix. When does the fiscal year end for Ocular Therapeutix?
Ocular Therapeutix's fiscal year ends in December. Where is Ocular Therapeutix based?
Ocular Therapeutix's address is: 15 Crosby Drive, Bedford, MA, United States, 01730 What is Ocular Therapeutix's ISIN number?
Ocular Therapeutix's international securities identification number is: US67576A1007 What is Ocular Therapeutix's CUSIP number?
Ocular Therapeutix's Committee on Uniform Securities Identification Procedures number is: 67576A100